Novartis CEO Vas Narasimhan said Tuesday that cannabis is not a priority for the Swiss drugmaker, despite its partnership with Canadian marijuana giant Tilray. HealthyReturns
Tilray is working with Novartis' generic drug business Sandoz and supplying non-smokable and non-combustible medical cannabis products where it is legally allowed. As a part of the deal announced in December, Tilray and Sandoz may co-brand certain products as well as develop new ones. It was the first major partnership between a pharmaceutical company and a cannabis business.
Narasimhan said he is instead trying to shape Novartis into a company that is "uniquely placed" in the health-care system, balancing between more common ailments such as dry-eye disease or migraines and more rare health concerns like gene diseases, which affects 350 million people worldwide. The Swiss drugmaker is expected this year to launch its gene therapy called Zolgensma for spinal muscular atrophy, a muscle-wasting disease and leading genetic cause of infant mortality, affecting one in every 11,000 live births. The treatment is estimated to boast a price tag between $1.5 million and $5 million.
In his interview Tuesday, Narasimhan said he's "hopeful" the company will get approval for the gene therapy soon. "We believe in the long run we can bring meaningful innovation ... and this can potentially cure kids of a disease," he added.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tilray CEO says marijuana companies lied about how much pot they could growTilray Inc. Chief Executive Brendan Kennedy said late Tuesday that the cannabis producer would be much larger if weed growers in Canada hadn’t lied about how...
Read more »
Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structureThe current global health system treats chronic diseases with a pay-as-you-go model, spreading costs over months and years. It's unprepared to pay for a surge of new, single-treatment therapies with the potential to provide a lifetime of benefit.
Read more »
Nissan says Saikawa retained as CEO, putting focus on Renault tiesNissan says Hiroto Saikawa retained as CEO, backing the protege of former boss Carlos Ghosn even as top shareholder Renault pushes for a change
Read more »
Huawei CEO says U.S. ‘underestimates’ the company’s strengthThe founder and chief executive of Huawei Technologies Co. says the U.S. government is underestimating the Chinese tech giant, and within a few years no one...
Read more »
Overstock CEO defends personal stock sale after shareholders question moveOverstock.com Inc Chief Executive Officer Patrick Byrne on Friday hit out at sha...
Read more »
Instacart and Whole Foods officially part ways, and the CEO says he's readyInstacart co-founder and CEO Apoorva Mehta says the company is ready for the split, and he is not looking at the IPO performance of other 'unicorns' going public this year.
Read more »
Gilead CEO insists federal government patent for HIV prevention pill Truvada is invalidDaniel O’Day testified before the House Oversight Committee, which called a hearing after The Washington Post reported that the government had opted against filing a patent infringement case on the drug’s use.
Read more »
Fingerprints and finances: next Wells Fargo CEO will be under regulatory microscopeFrom submitting their fingerprints to giving up their tax records, Wells Fargo &...
Read more »
Verizon CEO: 'Tens of thousands' of customers buying new 5G phonesVerizon is betting that customers will pay up for Samsung's new 5G smartphone.
Read more »
Airbus CEO: premature to talk about buying Bombardier Belfast plantThe head of Europe's Airbus said it was too early to talk about acquiring a...
Read more »
Former Goldman CEO Lloyd Blankfein on Trump's tariffs: 'I don't think he's wrong here'Former Goldman Sachs chief Lloyd Blankfein agrees with President Trump's stance on tariffs in the ongoing trade war with China, Politico reported Thursday.
Read more »